Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?

Published on Jan 30, 2020in European Journal of Nuclear Medicine and Molecular Imaging7.081
· DOI :10.1007/S00259-020-04702-4
Nicolas Aide28
Estimated H-index: 28
(French Institute of Health and Medical Research),
Michel De Pontdeville1
Estimated H-index: 1
Egesta Lopci26
Estimated H-index: 26
📖 Papers frequently viewed together
2 Citations
1 Citations
#1Angelo CastelloH-Index: 10
#2Sabrina RossiH-Index: 18
Last. Egesta LopciH-Index: 26
view all 5 authors...
Introduction: A new pattern of response, so-called hyper-progressive disease (HPD), is emerging during treatment with immune checkpoint inhibitors (ICI). Our aim was to investigate the prevalence of such phenomenon and to assess its association with clinical variables and metabolic parameters by (18)F-fludeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT). Methods: Data from 50 patients (34 male, 16 female, median age 73) with non-small cell lung carcinoma (NSCLC) an...
18 CitationsSource
#1Romain-David Seban (Université Paris-Saclay)H-Index: 8
#2Laura MezquitaH-Index: 17
Last. Benjamin BesseH-Index: 78
view all 14 authors...
Purpose We aimed to evaluate if imaging biomarkers on FDG PET are associated with clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).
30 CitationsSource
Purpose This prospective study aimed (1) to assess the non-small cell lung cancer (NSCLC) evolutive patterns to immunotherapy using FDG-PET and (2) to describe their association with clinical outcome.
16 CitationsSource
#1Rodney J. Hicks (University of Melbourne)H-Index: 90
#2Amir Iravani (University of Melbourne)H-Index: 15
Last. Shahneen Sandhu (University of Melbourne)H-Index: 52
view all 3 authors...
The complexity of the immune response and diversity of targets challenges conventional conceptual frameworks used in selecting and monitoring treatment with immune check-point inhibitors. The limitations of anatomic imaging in assessing response have been recognized. Varying patterns of response have been recognized. These patterns have different implications for the continuation and duration of therapy. Evidence supporting the role of (18)F-fluorodeoxyglucose Positron Emission Tomography/Comput...
7 CitationsSource
#1Kazuki Takada (Kyushu University)H-Index: 18
#2Gouji ToyokawaH-Index: 24
Last. Masaki Mori (Kyushu University)H-Index: 131
view all 13 authors...
To examine the association between 18F-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography/computed tomography (PET/CT) and the response to anti-programmed cell death-1 (PD-1) monoclonal antibody therapy in non-small cell lung cancer (NSCLC) patients, 89 patients with advanced or recurrent NSCLC were retrospectively analysed. Maximum standardized uptake value (SUVmax) in 18F-FDG PET/CT and the response to anti-PD-1 antibodies were recorded. A cut-off value of SUVmax was determine...
16 CitationsSource
#1Robert I. Haddad (Harvard University)H-Index: 73
#2Fernando Concha-Benavente (University of Pittsburgh)H-Index: 15
Last. Robert L. Ferris (University of Pittsburgh)H-Index: 92
view all 18 authors...
BACKGROUND: Response patterns with immune checkpoint inhibitors may be different from those with chemotherapy. Therefore, assessment of response to immunotherapy with the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, could result in premature treatment termination. The randomized, open-label, phase 3 CheckMate 141 trial (NCT02105636), which evaluated nivolumab in recurrent/metastatic squamous cell carcinoma of the head and neck after platinum therapy, allowed treatment beyo...
28 CitationsSource
#1Romain-David Seban (Université Paris-Saclay)H-Index: 8
#2John S Nemer (CUMC: Columbia University Medical Center)H-Index: 2
Last. Laurent Dercle (Université Paris-Saclay)H-Index: 21
view all 16 authors...
Purpose An imaging-based stratification tool is needed to identify melanoma patients who will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying biomarkers for survival and response evaluated in lymphoid tissue metabolism in spleen and bone marrow before initiation of therapy.
33 CitationsSource
#1Kimiteru Ito (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Rebecca Teng (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
Last. Wolfgang A. Weber (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 67
view all 10 authors...
: Immune checkpoint inhibitors (ICIs) are now commonly used to treat patients with metastatic malignant melanoma. Although concerns have been raised that the inflammatory response induced by ICIs may limit the ability of 18F-FDG PET/CT to assess tumor response, systematic analyses on the use of 18F-FDG PET/CT in this setting are mostly lacking. Thus, we set out to evaluate the association between tumor response on 18F-FDG PET/CT and prognosis in patients with metastatic malignant melanoma treate...
52 CitationsSource
#1Biagio Ricciuti (University of Perugia)H-Index: 24
#2Carlo GenovaH-Index: 22
Last. Rita Chiari (University of Perugia)H-Index: 3
view all 11 authors...
Abstract Introduction Treatment with immune checkpoint inhibitors beyond progression is associated with improved survival in patients with melanoma and clear-cell renal carcinoma. Whether this association exists for patients with non–small-cell lung cancer (NSCLC) is currently still unclear. Patients and Methods We performed a multi-institutional retrospective study based on landmark and multivariable analyses to evaluate the safety and efficacy of treatment with nivolumab beyond Response Evalua...
16 CitationsSource
#1Lucas GoldfarbH-Index: 3
#2Boris DuchemannH-Index: 9
Last. Michael Soussan (Université Paris-Saclay)H-Index: 27
view all 5 authors...
Immunotherapy represents a new therapeutic approach in non-small cell lung carcinoma (NSCLC) with the potential for prolonged benefits. Because of the systemic nature and heterogeneity of tumoral diseases, as well as the immune restoration process induced by immunotherapy, the assessment of therapeutic efficacy is challenging, and the role of FDG PET is not well established. We evaluated the potential of FDG PET to monitor NSCLC patients treated with a checkpoint inhibitor. This was a retrospect...
33 CitationsSource
Cited By3
#1David Lang (Johannes Kepler University of Linz)H-Index: 1
#2Gerald Wahl (Johannes Kepler University of Linz)H-Index: 1
Last. Michael Gabriel (Johannes Kepler University of Linz)H-Index: 27
view all 7 authors...
Cancer immunotherapy using immune-checkpoint inhibitors (ICI) has revolutionized the therapeutic landscape of various malignancies like non-small-cell lung cancer or melanoma. Pre-therapy response prediction and assessment during ICI treatment is challenging due to the lack of reliable biomarkers and the possibility of atypical radiological response patterns. Positron emission tomography/computed tomography (PET/CT) enables the visualization and quantification of metabolic lesion activity additi...
5 CitationsSource
#1Neeta Pandit-Taskar (Cornell University)H-Index: 42
#2Michael A. Postow (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 75
Imaging has played a critical role in the management of patients with cancer. Novel therapies are emerging rapidly; however, they are effective only in some patients. With the advent of new targeted therapeutics and immunotherapy, the limitations of conventional imaging methods are becoming more evident. FDG-PET imaging is restricted to the optimal assessment of immune therapies. There is a critical unmet need for pharmacodynamic and prognostic imaging biomarkers. Radiolabeled antibodies or smal...
#1Romain-David Seban (Université Paris-Saclay)H-Index: 8
#2Antoine Moya-Plana (French Institute of Health and Medical Research)H-Index: 11
Last. Laurent Dercle (CUMC: Columbia University Medical Center)H-Index: 21
view all 12 authors...
PURPOSE: To compare the prognostic value of imaging biomarkers derived from a quantitative analysis of baseline 18F-FDG-PET/CT in patients with mucosal melanoma (Muc-M) or cutaneous melanoma (Cut-M) treated with immune checkpoint inhibitors (ICIs). METHODS: In this retrospective monocentric study, we included 56 patients with non-resectable Muc-M (n = 24) or Cut-M (n = 32) who underwent baseline 18F-FDG-PET/CT before treatment with ICIs between 2011 and 2017. Parameters were extracted from (i) t...
16 CitationsSource